Correlation Between Amicus Therapeutics and Onconetix

Can any of the company-specific risk be diversified away by investing in both Amicus Therapeutics and Onconetix at the same time? Although using a correlation coefficient on its own may not help to predict future stock returns, this module helps to understand the diversifiable risk of combining Amicus Therapeutics and Onconetix into the same portfolio, which is an essential part of the fundamental portfolio management process.

By analyzing existing cross correlation between Amicus Therapeutics and Onconetix, you can compare the effects of market volatilities on Amicus Therapeutics and Onconetix and check how they will diversify away market risk if combined in the same portfolio for a given time horizon. You can also utilize pair trading strategies of matching a long position in Amicus Therapeutics with a short position of Onconetix. Check out your portfolio center. Please also check ongoing floating volatility patterns of Amicus Therapeutics and Onconetix.

Diversification Opportunities for Amicus Therapeutics and Onconetix

0.67

Correlation Coefficient

Amicus Therapeutics  Onconetix

Poor diversification

The 3 months correlation between Amicus and Onconetix is 0.67. Overlapping area represents the amount of risk that can be diversified away by holding Amicus Therapeutics and Onconetix in the same portfolio, assuming nothing else is changed. The correlation between historical prices or returns on Onconetix and Amicus Therapeutics is a relative statistical measure of the degree to which these equity instruments tend to move together. The correlation coefficient measures the extent to which returns on Amicus Therapeutics are associated (or correlated) with Onconetix. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when the price movement of Onconetix has no effect on the direction of Amicus Therapeutics i.e., Amicus Therapeutics and Onconetix go up and down completely randomly.

Pair Corralation between Amicus Therapeutics and Onconetix

Given the investment horizon of 90 days Amicus Therapeutics is expected to under-perform the Onconetix. But the stock apears to be less risky and, when comparing its historical volatility, Amicus Therapeutics is 5.87 times less risky than Onconetix. The stock trades about -0.1 of its potential returns per unit of risk. The Onconetix is currently generating about 0.06 of returns per unit of risk over similar time horizon. If you would invest  71.00  in Onconetix on October 9, 2024 and sell it today you would lose (1.00) from holding Onconetix or give up 1.41% of portfolio value over 90 days.

Time Period	3 Months [change]
Direction	Moves Together
Strength	Significant
Accuracy	100.0%
Values	Daily Returns

Amicus Therapeutics  vs.  Onconetix

Amicus Therapeutics

Risk-Adjusted Performance

0 of 100

Very Weak

Over the last 90 days Amicus Therapeutics has generated negative risk-adjusted returns adding no value to investors with long positions. In spite of latest weak performance, the Stock's essential indicators remain sound and the latest tumult on Wall Street may also be a sign of longer-term gains for the firm shareholders.

Onconetix

Risk-Adjusted Performance

0 of 100

Very Weak

Over the last 90 days Onconetix has generated negative risk-adjusted returns adding no value to investors with long positions. In spite of fragile performance in the last few months, the Stock's fundamental indicators remain very healthy which may send shares a bit higher in February 2025. The recent disarray may also be a sign of long period up-swing for the firm investors.

Pair Trading with Amicus Therapeutics and Onconetix

The main advantage of trading using opposite Amicus Therapeutics and Onconetix positions is that it hedges away some unsystematic risk. Because of two separate transactions, even if Amicus Therapeutics position performs unexpectedly, Onconetix can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Onconetix will offset losses from the drop in Onconetix's long position.

The idea behind Amicus Therapeutics and Onconetix pairs trading is to make the combined position market-neutral, meaning the overall market's direction will not affect its win or loss (or potential downside or upside). This can be achieved by designing a pairs trade with two highly correlated stocks or equities that operate in a similar space or sector, making it possible to obtain profits through simple and relatively low-risk investment.

Check out your portfolio center.

Note that this page's information should be used as a complementary analysis to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Premium Stories module to follow Macroaxis premium stories from verified contributors across different equity types, categories and coverage scope.